tiprankstipranks
Trending News
More News >
Faes Farma SA (ES:FAE)
BME:FAE

Faes Farma (FAE) AI Stock Analysis

Compare
13 Followers

Top Page

ES

Faes Farma

(BME:FAE)

Rating:80Outperform
Price Target:
€5.00
▲(16.55%Upside)
Faes Farma's strong financial performance, characterized by robust growth and a solid balance sheet, is the primary driver of its stock score. Technical analysis supports this strength with indications of a stable uptrend. The valuation is favorable with a reasonable P/E ratio and a good dividend yield, enhancing its attractiveness. Overall, the company is well-positioned in the market, supported by its solid financials and stable technical indicators.

Faes Farma (FAE) vs. iShares MSCI Spain ETF (EWP)

Faes Farma Business Overview & Revenue Model

Company DescriptionFaes Farma, S.A., a pharmaceutical company, researches, develops, produces, and commercializes pharmaceutical products and raw materials in Spain and internationally. The company's product portfolio includes prescription drugs, generic drugs, over-the-counter (OTC) drugs, food supplements, baby foods, and other health products. It offers Actimag, a magnesium pidolate; Bilaxten, an anti-allergic; Bronquidiazina CR, an anti-infective; Claversal for ulcerative colitis and Crohn's disease; Dezacor, a corticoid; Dolotren, an anti-inflammatory; Dolotren Gel; Dynamogen, an anti-anorexic; Ferroprotina, an anti-anaemic; Hidroferol; Lipofen; Positon for dermatitis; strength builder products, such as Potenciator and Surmenalit; Pruina, a laxative; Robaxisal Compuesto, a muscle relaxant and analgesic; Trausan, a citicoline; Venosmil, a venous vasoprotector; Venosmil Gel; and Yendol, an anti-flu. The company also provides Bilastine, an antihistamine molecule for the treatment of allergic rhino conjunctivitis and urticarial; Calcifediol for bone metabolism; Deflazacort to treat osteoarticular disease; Hidrosmin for venous insufficiency; and Mesalazine to treat digestion problems. It also exports its products. Faes Farma, S.A. was founded in 1933 and is headquartered in Leioa, Spain.
How the Company Makes MoneyFaes Farma generates revenue primarily through the sale of its pharmaceutical products. The company's revenue model is based on the production and distribution of both branded and generic medications across various therapeutic areas. Key revenue streams include prescription drugs, which are sold through contracts with healthcare providers and pharmacies, and OTC products, which are available directly to consumers. Additionally, Faes Farma has a significant presence in the veterinary sector, selling animal health products. The company also earns income from its nutritional supplements segment. Strategic partnerships and collaborations with other pharmaceutical companies enhance its research and development capabilities and expand its product portfolio, contributing to its overall earnings.

Faes Farma Financial Statement Overview

Summary
Income Statement
Balance Sheet
Cash Flow
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
597.59M493.65M451.17M438.75M398.56M380.24M
Gross Profit
347.69M326.54M297.12M282.01M252.40M239.84M
EBIT
161.09M107.08M103.75M101.92M98.44M90.79M
EBITDA
162.70M128.33M122.93M121.35M110.84M100.26M
Net Income Common Stockholders
118.42M111.36M91.90M89.50M82.39M72.55M
Balance SheetCash, Cash Equivalents and Short-Term Investments
47.75M72.14M47.75M84.10M73.41M93.14M
Total Assets
776.03M853.08M776.03M725.67M641.76M564.15M
Total Debt
8.23M1.99M23.90M32.69M16.44M13.89M
Net Debt
-26.41M-62.23M-10.75M-33.73M-53.81M-77.32M
Total Liabilities
112.44M126.46M112.68M123.39M103.70M91.27M
Stockholders Equity
662.36M725.87M662.36M601.08M536.53M471.39M
Cash FlowFree Cash Flow
44.47M75.95M-1.22M25.84M20.23M52.77M
Operating Cash Flow
105.82M115.47M100.97M106.79M79.64M78.49M
Investing Cash Flow
-55.22M-34.18M-97.36M-92.17M-83.48M-25.78M
Financing Cash Flow
-24.17M-51.71M-35.38M-18.46M-17.12M-14.35M

Faes Farma Technical Analysis

Technical Analysis Sentiment
Positive
Last Price4.29
Price Trends
50DMA
4.11
Positive
100DMA
3.81
Positive
200DMA
3.67
Positive
Market Momentum
MACD
0.05
Positive
RSI
57.53
Neutral
STOCH
35.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ES:FAE, the sentiment is Positive. The current price of 4.29 is above the 20-day moving average (MA) of 4.26, above the 50-day MA of 4.11, and above the 200-day MA of 3.67, indicating a bullish trend. The MACD of 0.05 indicates Positive momentum. The RSI at 57.53 is Neutral, neither overbought nor oversold. The STOCH value of 35.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ES:FAE.

Faes Farma Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
ESFAE
80
Outperform
€1.34B11.9916.04%2.97%9.42%20.43%
54
Neutral
$5.31B3.29-45.39%2.79%16.77%-0.07%
€2.37B232.500.69%1.33%
€6.32B26.773.37%
€263.54M23.595.11%1.24%
€2.80B20.2525.24%1.62%
$1.72B78.7510.15%0.73%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ES:FAE
Faes Farma
4.29
0.64
17.37%
GB:0O9B
Almirall
11.16
1.70
17.97%
GB:0RDV
Grifols
7.68
1.12
17.07%
GB:0RB1
LABORATORIO REIG JOFRE
3.19
0.13
4.25%
GB:0ILL
Laboratorios Farmaceuticos Rovi
55.20
-32.91
-37.35%
PHMMF
Pharma Mar SA
95.77
55.22
136.18%

Faes Farma Corporate Events

Faes Farma Expands Ophthalmology Portfolio with Laboratorios Edol Acquisition
Jun 4, 2025

Faes Farma, S.A. has completed the acquisition of Laboratorios Edol, a leading Portuguese ophthalmology company, as part of its strategic plan to enhance its presence in Portugal and expand its international growth. This acquisition, valued at 75 million euros, is expected to create synergies with Faes Farma’s current R&D efforts and support business growth in new therapeutic areas.

Faes Farma Announces 2025 General Shareholders’ Meeting
May 19, 2025

Faes Farma, S.A. has announced the convening of its General Shareholders’ Meeting, scheduled for June 24 or 25, 2025, to discuss and approve key financial and management reports for the 2024 fiscal year. The meeting will also address the appointment of a new independent director and include an advisory vote on the directors’ remuneration report, reflecting the company’s ongoing governance and strategic planning efforts.

Faes Farma Announces Q1 2025 Results Webcast
Apr 29, 2025

Faes Farma has announced a webcast for analysts and investors to present its first quarter 2025 results. The webcast, featuring key company executives, will include a Q&A session and aims to provide insights into the company’s financial performance and strategic direction.

Faes Farma Unveils Strategic Plan for 2025-2030
Apr 22, 2025

Faes Farma held its Capital Markets Day to outline its strategic plan for 2025-2030, emphasizing transformation and future growth. The plan focuses on four strategic axes, highlighting the company’s ambition to strengthen its organizational culture and expand its international business operations.

Faes Farma Unveils New Strategic Plan at Capital Markets Day
Apr 22, 2025

Faes Farma, a company operating in the pharmaceutical industry, has announced its Capital Markets Day event to unveil the Group’s new Strategic Plan. This event will outline the company’s objectives and growth strategies for the upcoming years, potentially impacting its market positioning and providing insights for stakeholders.

Faes Farma Acquires Portuguese Ophthalmology Leader Laboratorios Edol
Mar 25, 2025

Faes Farma, S.A. has announced the acquisition of Laboratorios Edol, a leading Portuguese ophthalmology laboratory, for 75 million euros. This strategic move is expected to double Faes Farma’s sales and EBITDA in Portugal, enhance its international market presence, and create synergies with its current R&D team, particularly in the growing field of ophthalmology.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.